Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival
Article first published online: 20 OCT 2008
© 2008 Japanese Society of Neuropathology
Volume 29, Issue 3, pages 242–247, June 2009
How to Cite
Holmlund, C., Haapasalo, H., Yi, W., Raheem, O., Brännström, T., Bragge, H., Henriksson, R. and Hedman, H. (2009), Cytoplasmic LRIG2 expression is associated with poor oligodendroglioma patient survival. Neuropathology, 29: 242–247. doi: 10.1111/j.1440-1789.2008.00970.x
- Issue published online: 13 MAY 2009
- Article first published online: 20 OCT 2008
- Received 24 June 2008; revised and accepted 12 August 2008; published online 20 October 2008.
- LRIG proteins;
- patient survival
The three leucine-rich repeats and immunoglobulin-like domains (LRIG) genes encode integral membrane proteins. Of these, LRIG1 negatively regulates growth factor signaling and is implicated as a tumor suppressor in certain malignancies. In astrocytic tumors, the subcellular distribution of LRIG proteins is associated with specific clinicopathological features and patient survival. The role of LRIG proteins in oligodendroglioma has not previously been studied. Here we used immunohistochemistry to analyze the expression of the LRIG proteins in 63 oligodendroglial tumors, and evaluated possible associations between LRIG protein expression and clinicopathological parameters. Notably, cytoplasmic LRIG2 expression was found to be an independent prognostic factor associated with poor oligodendroglioma patient survival. This is the first report of an LRIG protein showing a negative effect on survival, suggesting that LRIG2 might have a function different from that of LRIG1, and possibly contributing to the etiology of oligodendroglioma.